A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
Public ClinicalTrials.gov record NCT05048797. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)
Study identification
- NCT ID
- NCT05048797
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 454 participants
Conditions and interventions
Interventions
- Carboplatin Drug
- Cisplatin Drug
- Pembrolizumab Drug
- Pemetrexed Drug
- Trastuzumab Deruxtecan Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 123 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 27, 2021
- Primary completion
- Apr 29, 2026
- Completion
- Jul 29, 2027
- Last update posted
- Apr 2, 2026
2021 – 2027
United States locations
- U.S. sites
- 19
- U.S. states
- 9
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Anchorage | Alaska | 99508 | — |
| Research Site | Los Alamitos | California | 90720 | — |
| Research Site | Los Angeles | California | 90048 | — |
| Research Site | Orange | California | 92868 | — |
| Research Site | San Francisco | California | 94143 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Silver Spring | Maryland | 20910 | — |
| Research Site | Boston | Massachusetts | 02215 | — |
| Research Site | Ann Arbor | Michigan | 48109 | — |
| Research Site | Basking Ridge | New Jersey | 07920 | — |
| Research Site | Middletown | New Jersey | 07748 | — |
| Research Site | Montvale | New Jersey | 07645 | — |
| Research Site | New Brunswick | New Jersey | 08901 | — |
| Research Site | Commack | New York | 11725 | — |
| Research Site | Harrison | New York | 10604 | — |
| Research Site | New York | New York | 10065 | — |
| Research Site | Uniondale | New York | 11553 | — |
| Research Site | Pittsburgh | Pennsylvania | 15232 | — |
| Research Site | Dallas | Texas | 75246 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 111 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05048797, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05048797 live on ClinicalTrials.gov.